Increasing trends in the use of Precivia® intravitreal injection assist device across the UK

Panayiotis Maghsoudlou[1], Ibrar Ahmed[2], Nimish Shah[2]

[1]Department of Ophthalmology, Cheltenham General Hospital, Gloucestershire Hospitals NHS Foundation Trust. Great Western Hospital NHS Foundation Trust, Swindon, UK [2]

Introduction

- As the most frequently performed outpatient procedure in the UK, the demand for intravitreal anti-VEGF injections continues to rise[1].
- To meet this demand, injection assist devices such as Precivia® are increasingly adopted to aid in their prompt and safe delivery.

Aim

To retrospectively review the usage of the Precivia® intravitreal injection assist device across two district general hospitals and its distribution across the UK over a five-year period.

Methods

- A retrospective review was undertaken of all Precivia® assisted anti-VEGF injections delivered at Cheltenham General Hospital (CGH) and Great Western Hospital (GWH) between 2015 and 2020.
- The number of devices distributed across the UK over these 5 years were collated from the device distributor.




Figure 1 *- Schematic representation of the Precivia® intravitreal injection assist device, manufactured by FCI Ophthalmics USA.[2]*

Table 1 *- Number of Precivia®-assisted injections over the five-year study period across two NHS hospital trusts and its distribution across the UK.*

Precivia®-assisted Injections	Year				
	2015 - 2016	2016 - 2017	2017 - 2018	2018 - 2019	2019 - 2020
Great Western Hospital	4232	5117	5437	5878	6259
Cheltenham General Hospital	5947	7058	9893	11,503	13,567
Distribution across the UK	42150	68125	72575	88325	112850

Results




Figure 2 *- Usage of the Precivia® intravitreal injection assist device for intravitreal injections in two NHS hospital trusts and its distribution across the UK.*

Discussion

- In CGH, 47,968 injections were administered with Precivia®: demonstrating a 128.13% increase in the device use over the five-year period.
- In GWH, 26,923 injections were administered with Precivia®: observing a 47.89% increase in Precivia® injections over the five-year period.
- 173.31% increase in five years was observed in the number of Precivia® devices distributed across the UK suggesting greater popularity.

Conclusions

An increasing trend in the use of the Precivia® device is observed across the UK to deliver a large-volume intravitreal injection service.

References

1. National Institute for Health and Care Excellence. Age-related macular degeneration. 2018. Available at: https://www.nice.org.uk/guidance/ng82/
2. Precivia® [Internet]. FCI. Available from: https://fci-ophthalmics.com/products/precivia/